Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
NRIX

NRIX - Nurix Therapeutics, Inc. Stock Price, Fair Value and News

20.77USD-0.38 (-1.80%)Market Closed

Market Summary

NRIX
USD20.77-0.38
Market Closed
-1.80%

NRIX Alerts

  • 2 major insider sales recently.
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

NRIX Stock Price

View Fullscreen

NRIX RSI Chart

NRIX Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-8.11

Price/Sales (Trailing)

16.54

EV/EBITDA

-8.56

Price/Free Cashflow

-12.63

NRIX Price/Sales (Trailing)

NRIX Profitability

EBT Margin

-186.55%

Return on Equity

-44.51%

Return on Assets

-32.29%

Free Cashflow Yield

-7.92%

NRIX Fundamentals

NRIX Revenue

Revenue (TTM)

80.9M

Rev. Growth (Yr)

30.74%

Rev. Growth (Qtr)

9.41%

NRIX Earnings

Earnings (TTM)

-165.0M

Earnings Growth (Yr)

-83.49%

Earnings Growth (Qtr)

-7.29%

Breaking Down NRIX Revenue

Last 7 days

-12.8%

Last 30 days

12.6%

Last 90 days

52.8%

Trailing 12 Months

114.7%

How does NRIX drawdown profile look like?

NRIX Financial Health

Current Ratio

5.57

NRIX Investor Care

Shares Dilution (1Y)

33.63%

Diluted EPS (TTM)

-2.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202480.9M000
202341.7M60.9M68.6M77.0M
202234.4M38.7M39.2M38.6M
202120.0M22.9M29.0M29.8M
202024.7M19.5M13.0M17.8M
201900031.1M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Nurix Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 17, 2024
kunkel lori anne
gifted
-
-
-54,027
-
Jul 01, 2024
ring christine
acquired
10,713
1.86
5,760
chief legal officer
Jul 01, 2024
ring christine
sold
-119,837
20.805
-5,760
chief legal officer
Jun 20, 2024
van houte hans
sold
-400,216
20.0108
-20,000
chief financial officer
Jun 13, 2024
ring christine
acquired
3,467
1.86
1,864
chief legal officer
Jun 13, 2024
ring christine
sold
-31,721
17.0178
-1,864
chief legal officer
Jun 12, 2024
ring christine
acquired
3,534
1.86
1,900
chief legal officer
Jun 12, 2024
ring christine
sold
-32,319
17.01
-1,900
chief legal officer
Jun 05, 2024
ring christine
sold
-6,801
17.0025
-400
chief legal officer
Jun 05, 2024
ring christine
acquired
744
1.86
400
chief legal officer

1–10 of 50

Which funds bought or sold NRIX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 12, 2024
SG Americas Securities, LLC
added
364
1,828,000
2,154,000
0.01%
Jul 10, 2024
CWM, LLC
new
-
3,000
3,000
-%
Jul 02, 2024
GAMMA Investing LLC
added
299
78,505
95,292
0.01%
Jul 01, 2024
Legal & General Group Plc
reduced
-2.23
27,940
99,107
-%
May 29, 2024
Opaleye Management Inc.
new
-
3,927,990
3,927,990
0.86%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
67.6
80,239
138,239
0.02%
May 17, 2024
Ikarian Capital, LLC
new
-
4,410,000
4,410,000
0.48%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-24.22
61,326
833,696
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.92
-10,503
70,354
-%
May 16, 2024
COMERICA BANK
unchanged
-
421
1,415
-%

1–10 of 48

Are Funds Buying or Selling NRIX?

Are funds buying NRIX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NRIX
No. of Funds

Unveiling Nurix Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 07, 2024
blackrock inc.
10.2%
6,042,150
SC 13G/A
Feb 14, 2024
deep track capital, lp
6.18%
2,997,830
SC 13G/A
Feb 14, 2024
price t rowe associates inc /md/
4.9%
2,391,866
SC 13G/A
Feb 14, 2024
redmile group, llc
9.9%
5,021,886
SC 13G/A
Feb 14, 2024
baker bros. advisors lp
9.99%
4,952,452
SC 13G/A
Feb 14, 2024
sands arthur t
5.4%
2,707,896
SC 13G
Feb 13, 2024
vanguard group inc
5.36%
2,598,097
SC 13G
Feb 09, 2024
morgan stanley
6.4%
3,099,198
SC 13G
Feb 09, 2024
wasatch advisors lp
-
0
SC 13G/A
Jan 29, 2024
ark investment management llc
6.59%
3,194,999
SC 13G

Recent SEC filings of Nurix Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Jul 18, 2024
4
Insider Trading
Jul 11, 2024
10-Q
Quarterly Report
Jul 11, 2024
424B5
Prospectus Filed
Jul 11, 2024
8-K
Current Report
Jul 01, 2024
144
Notice of Insider Sale Intent
Jul 01, 2024
4
Insider Trading
Jun 20, 2024
144
Notice of Insider Sale Intent
Jun 20, 2024
4
Insider Trading
Jun 17, 2024
8-K
Current Report
Jun 13, 2024
4
Insider Trading

Peers (Alternatives to Nurix Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Nurix Therapeutics, Inc. News

Latest updates
Defense World3 hours ago
American Banking and Market News16 Jul 202408:33 am
American Banking and Market News16 Jul 202408:33 am

Nurix Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue9.4%16,585,00015,159,00018,467,00030,676,00012,685,0006,783,00010,791,00011,432,0009,621,0007,396,00010,252,0007,091,0005,011,0006,689,0004,085,0004,182,0002,864,0001,862,00010,580,0009,439,0009,234,000
Operating Expenses2.2%61,804,00060,493,00058,479,00057,441,00055,637,00055,473,00057,509,00057,147,00052,365,00045,349,00039,249,00033,505,00029,533,00026,697,00023,277,00017,412,00015,417,000-13,192,000--
  S&GA Expenses9.5%11,799,00010,780,00010,623,00011,678,0009,821,0009,367,0009,748,0009,654,0009,228,0008,818,0008,343,0007,511,0006,530,0006,251,5004,338,0003,270,0002,450,000-2,184,000--
  R&D Expenses0.6%50,005,00049,713,00047,856,00045,763,00045,816,00046,106,00047,761,00047,493,00043,137,00036,531,00030,906,00025,994,00023,003,00020,445,50018,939,00014,142,00012,967,000-11,008,000--
EBITDA Margin7.7%-1.80-1.95-2.19-2.47-4.14-4.53-4.25-3.89-3.85-3.84-3.33----------
Income Taxes-90,000--------44,000-123,000139,00071,00053,000--20,587,00011,000-10,000--
Earnings Before Taxes-Infinity%-41,428,000---24,277,000-40,733,000-46,717,000-45,709,000-45,401,000-42,533,000-37,658,000-28,958,000-26,243,000-24,204,000-19,873,000-18,517,000-13,007,000-12,380,000--2,417,000--
EBT Margin7.4%-1.89-2.04-2.29-2.58-4.28-4.67-4.37-3.99-3.94-3.93-3.42----------
Net Income1.0%-41,518,000-41,956,000-36,982,000-24,277,000-40,733,000-46,717,000-45,709,000-45,401,000-42,533,000-37,702,000-28,835,000-26,382,000-24,275,000-19,914,000-18,517,0007,580,000-12,391,000-13,519,000-2,427,000-3,068,000-2,685,000
Net Income Margin4.3%-1.79-1.87-2.17-2.58-4.28-4.67-4.37-3.99-3.94-3.94-3.42----------
Free Cashflow-286.0%-44,835,00024,104,000-43,592,000-19,549,000-50,729,000-40,520,000-49,726,000-35,703,000-46,102,000-31,773,000-31,837,000----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Assets63.4%51131335630835137041745939443847749351839739641244.00
  Current Assets79.4%45025129626829028831835530728031135839631129836439.00
    Cash Equivalents134.5%11750.0055.0042.0059.0034.0064.0048.0042.0079.0081.0014718812611926635.00
  Net PPE3.8%19.0018.0017.0017.0018.0018.0017.0017.0016.0014.0011.0010.008.007.007.007.004.00
Liabilities-2.5%14014415574.0091.0096.0011311712813213411812012710610454.00
  Current Liabilities-7.8%81.0088.0087.0061.0072.0065.0071.0068.0073.0066.0066.0051.0047.0048.0045.0041.0016.00
Shareholder's Equity119.7%371169200234260274304343267306342375398270290308-
  Retained Earnings-7.6%-631-586-545-503-466-442-401-354-308-263-220-183-154-127-103-83.78-60.46
  Additional Paid-In Capital32.6%1,0027567467387287197097015795715645585523983943913.00
Shares Outstanding31.0%64.0049.0049.0049.0048.0054.0047.0047.0045.0045.0045.0042.00-----
Float-----471---444---1,100----
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Cashflow From Operations5.4%-39.70-41.9527.00-41.13-18.47-48.45-37.95-46.31-32.91-42.63-30.91-29.97-31.538.00-20.48-6.14-14.4341.00--
  Share Based Compensation13.1%9.008.008.008.009.008.008.007.007.006.005.004.004.003.003.001.000.000.00--
Cashflow From Investing-469.1%-13136.00-14.3723.0044.0016.0055.00-63.08-4.7640.00-36.52-12.23-57.11-2.39-124-108-2.34-19.42--
Cashflow From Financing14539.9%2382.000.002.000.001.00-0.131150.001.001.002.001501.00-1.132201200.00--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

NRIX Income Statement

2024-05-31
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended6 Months Ended
May 31, 2024
May 31, 2023
May 31, 2024
May 31, 2023
Total revenue$ 12,092,000$ 30,676,000$ 28,677,000$ 43,361,000
Operating expenses:    
Research and development48,922,00045,763,00098,927,00091,579,000
General and administrative11,710,00011,678,00023,509,00021,499,000
Total operating expenses60,632,00057,441,000122,436,000113,078,000
Loss from operations(48,540,000)(26,765,000)(93,759,000)(69,717,000)
Interest and other income, net4,084,0002,488,0007,875,0004,707,000
Loss before income taxes(44,456,000)(24,277,000)(85,884,000)(65,010,000)
Provision for income taxes90,0000180,0000
Net loss$ (44,546,000)$ (24,277,000)$ (86,064,000)$ (65,010,000)
Net loss per share, basic (in USD per share)$ (0.71)$ (0.45)$ (1.47)$ (1.20)
Net loss per share, diluted (in USD per share)$ (0.71)$ (0.45)$ (1.47)$ (1.20)
Weighted-average number of shares outstanding, basic (in shares)62,377,55154,259,04558,660,90054,144,909
Weighted-average number of shares outstanding, diluted (in shares)62,377,55154,259,04558,660,90054,144,909
Collaboration revenue    
Total revenue$ 12,092,000$ 10,676,000$ 28,677,000$ 23,361,000
License revenue    
Total revenue$ 0$ 20,000,000$ 0$ 20,000,000

NRIX Balance Sheet

2024-05-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
May 31, 2024
Nov. 30, 2023
Current assets:  
Cash and cash equivalents$ 116,790$ 54,627
Marketable securities, current326,349233,281
Prepaid expenses and other current assets7,0787,595
Total current assets450,217295,503
Marketable securities, non‑current9,3807,421
Operating lease right-of-use assets28,83531,142
Property and equipment, net18,55716,808
Restricted cash901901
Other assets3,1413,823
Total assets511,031355,598
Current liabilities:  
Accounts payable2,8136,401
Accrued expenses and other current liabilities23,26324,970
Operating lease liabilities, current7,9347,489
Deferred revenue, current46,76948,098
Total current liabilities80,77986,958
Operating lease liabilities, net of current portion20,88523,125
Deferred revenue, net of current portion38,67445,022
Total liabilities140,338155,105
Commitments and contingencies (Note 6)
Stockholdersʼ equity:  
Preferred stock, $0.001 par value— 10,000,000 shares authorized as of May 31, 2024 and November 30, 2023; no shares issued and outstanding as of May 31, 2024 and November 30, 202300
Common stock, $0.001 par value— 500,000,000 shares authorized as of May 31, 2024 and November 30, 2023; 64,356,535 and 48,718,552 shares issued and outstanding as of May 31, 2024 and November 30, 2023, respectively6449
Additional paid-in capital1,002,028746,299
Accumulated other comprehensive loss(135)(655)
Accumulated deficit(631,264)(545,200)
Total stockholdersʼ equity370,693200,493
Total liabilities and stockholdersʼ equity$ 511,031$ 355,598
NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
 CEO
 WEBSITEnurixtx.com
 INDUSTRYBiotechnology
 EMPLOYEES297

Nurix Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Nurix Therapeutics, Inc.? What does NRIX stand for in stocks?

NRIX is the stock ticker symbol of Nurix Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nurix Therapeutics, Inc. (NRIX)?

As of Fri Jul 19 2024, market cap of Nurix Therapeutics, Inc. is 1.34 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NRIX stock?

You can check NRIX's fair value in chart for subscribers.

What is the fair value of NRIX stock?

You can check NRIX's fair value in chart for subscribers. The fair value of Nurix Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nurix Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NRIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nurix Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether NRIX is over valued or under valued. Whether Nurix Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Nurix Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NRIX.

What is Nurix Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, NRIX's PE ratio (Price to Earnings) is -8.11 and Price to Sales (PS) ratio is 16.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NRIX PE ratio will change depending on the future growth rate expectations of investors.